749 completed. 749 Phase 1, 209 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 749 | Completed 749 |
| Phase 2 | 209 | Completed 209 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia 14C-bleximenib, bleximenib - Acute Lymphoblastic Leukemia, Acute Leukemias | Phase 1 | Completed | Janssen Research & Development, LLC | 6 | 2025-11-18 | 2026-09-25 |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | Completed | National Research Center for Hematology, Russia | 58 | 2024-11-26 | 2026-02-09 |
| Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers ZE50-0134 or placebo, Rabeprazole 20 mg, Itraconazole (200 mg) - Healthy | Phase 1 | Completed | Lomond Therapeutics Holdings, Inc. | 104 | 2024-05-21 | 2025-12-05 |
| A Study of PD5K3 in Healthy Adult Volunteers PD5K3, Placebo, Pegaspargase - Lymphoblastic Leukemia, Acute, Lymphoblastic Lymphoma | Phase 1 | Completed | Chongqing Peg-Bio Biopharm Co., Ltd. | 28 | 2023-11-27 | 2024-07-30 |
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2023-09-12 | 2026-01-26 |
| Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors KT-253 - Myeloid Malignancies, Acute Lymphocytic Leukemia | Phase 1 | Completed | Kymera Therapeutics, Inc. | 52 | 2023-05-15 | 2025-01-27 |
| Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies Fludarabine, Cyclophosphamide, PRGN-3007 - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 3 | 2023-01-25 | 2026-02-06 |
| ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) ABC008 - T-cell Large Granular Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Abcuro, Inc. | 21 | 2022-09-28 | 2026-05-06 |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia CAR-NK-CD19 Cells - Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai Simnova Biotechnology Co.,Ltd. | 2 | 2022-07-21 | 2022-11-28 |
| Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors KT-333 - Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Completed | Kymera Therapeutics, Inc. | 56 | 2022-05-19 | 2025-03-19 |
| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies anti-CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 14 | 2022-05-04 | 2025-06-06 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Syndax Pharmaceuticals | 30 | 2022-03-09 | 2024-08-13 |
| A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL WU-CART-007 - T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 | Completed | Allotera Therapeutics | 28 | 2022-01-14 | 2025-09-30 |
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy BMS-986345, Duvelisib - Non Hodgkin Lymphoma, Hodgkin Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 14 | 2021-11-18 | 2025-12-04 |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers LOXO-338, Pirtobrutinib - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone | Phase 1 | Completed | Eli Lilly and Company | 27 | 2021-09-30 | 2026-10-06 |
| Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings vaccine COMIRNATY® (BNT162b2) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 76 | 2021-09-29 | 2024-06-26 |
| Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma chimeric antigen receptor T cell treatment - T Cell Lymphoma, T-cell Leukemia | Phase 1 | Completed | Beijing Boren Hospital | 16 | 2021-09-14 | 2024-11-14 |
| Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients HDMP + rituximab as a means of debulking prior to initiating venetoclax. - Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 1 | Completed | University of California, San Diego | 4 | 2021-09-02 | 2026-08-20 |
| A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL JNJ-67856633, Ibrutinib - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin | Phase 1 | Completed | Janssen Research & Development, LLC | 45 | 2021-07-28 | 2025-08-21 |
| Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia Palbociclib, Dexamethasone, Bortezomib - Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia | Phase 1 | Completed | Tanja Andrea Gruber | 2 | 2021-07-09 | 2026-04-17 |
Showing 20 of 749. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (444) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (434) · Lymphoma, Non-Hodgkin (260) · Leukemia, Myeloid, Acute (233) · Lymphoma, Follicular (225) · Lymphoma, Mantle-Cell (225) · Leukemia (224) · Lymphoma, Large B-Cell, Diffuse (202) · Lymphoma, B-Cell, Marginal Zone (198) · Lymphoma (195) · Burkitt Lymphoma (185) · Hodgkin Disease (168) · Lymphoma, Large-Cell, Immunoblastic (150) · Myelodysplastic Syndromes (119) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (115)
Hemic and Lymphatic Diseases (749) · Neoplasms by Histologic Type (748) · Immunoproliferative Disorders (746) · Hematologic Diseases (745) · Lymphatic Diseases (745) · Immune System Diseases (743) · Lymphoproliferative Disorders (741) · Neoplasms (709) · Pathologic Processes (561) · Pathological Conditions, Signs and Symptoms (561) · Disease Attributes (559) · Chronic Disease (532) · Leukemia (525) · Leukemia, B-Cell (429)
Cyclophosphamide (78) · Rituximab (73) · fludarabine phosphate (66) · Cytarabine (49) · Filgrastim (40) · Peripheral Blood Stem Cell Transplantation (40) · Etoposide (37) · fludarabine (37) · Methotrexate (30) · Vincristine (29) · Bortezomib (27) · Clofarabine (27) · Lenalidomide (27) · Bendamustine Hydrochloride (25) · Dexamethasone (23)
National Cancer Institute (NCI) (111) · M.D. Anderson Cancer Center (37) · Fred Hutchinson Cancer Center (29) · Memorial Sloan Kettering Cancer Center (19) · Mayo Clinic (13) · National Institutes of Health Clinical Center (CC) (13) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (11) · City of Hope Medical Center (10) · Dana-Farber Cancer Institute (10) · Celgene (8) · Gilead Sciences (8) · Janssen Research & Development, LLC (8) · National Heart, Lung, and Blood Institute (NHLBI) (8) · St. Jude Children's Research Hospital (8) · AbbVie (7)
United States (632) · Canada (51) · Germany (37) · United Kingdom (36) · France (35) · Australia (34) · Italy (26) · Spain (21) · China (18) · Japan (17) · Netherlands (17) · South Korea (15) · Poland (13) · Switzerland (12) · Austria (11)
Brenda Sandmaier (6) · Mario Sznol, MD (5) · Shivaani Kummar, MD (5) · Steven Grant, MD (5) · Judith E. Karp, MD (4) · Scott Stromatt, MD (4) · Brenda Cooper (3)
PMID 34515338, PMID 32499241, PMID 34398557, PMID 19238148, PMID 19949018, PMID 20028764, PMID 20882050, PMID 21816833, PMID 22002018, PMID 23886836, PMID 24055823, PMID 25317870, PMID 25381051, PMID 26182309, PMID 26813675, PMID 27482888, PMID 31023700, PMID 33883258, PMID 34687939, PMID 34780125, PMID 37486616, PMID 39368878, PMID 10552943, PMID 10764422, PMID 11410496, PMID 11756154, PMID 11896112, PMID 12114413, PMID 12171484, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15231574, PMID 15466934, PMID 15570084, PMID 16051743, PMID 16061911, PMID 16135477, PMID 16186597, PMID 16278404, PMID 16533779, PMID 16731764, PMID 16775234, PMID 16775235, PMID 17020988, PMID 17119113, PMID 17312328, PMID 17562873, PMID 17640728, PMID 17679729
P30CA015704 (14), U01CA070095 (12), P30CA006973 (11), U01CA076576 (10), U01CA069912 (9), P30CA016672 (8), P30CA033572 (8), U01CA062461 (8), U01CA062502 (8), U01CA097452 (8), U01CA062491 (7), U01CA062505 (7), P30CA015083 (6), P30CA016058 (6), 2015 (5)